Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
140 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Candidiasis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Candidiasis - Pipeline Review, H2 2015', provides an overview of the Candidiasis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Candidiasis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Candidiasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Candidiasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Candidiasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Candidiasis Overview 8 Therapeutics Development 9 Pipeline Products for Candidiasis - Overview 9 Pipeline Products for Candidiasis - Comparative Analysis 10 Candidiasis - Therapeutics under Development by Companies 11 Candidiasis - Therapeutics under Investigation by Universities/Institutes 13 Candidiasis - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Candidiasis - Products under Development by Companies 18 Candidiasis - Products under Investigation by Universities/Institutes 21 Candidiasis - Companies Involved in Therapeutics Development 22 Aureogen Biosciences, Inc. 22 Bakker Medical Srl 23 Biomar Microbial Technologies 24 Cellceutix Corporation 25 Cidara Therapeutics, Inc. 26 Daewoong Pharmaceutical Co., Ltd. 27 Eisai Co., Ltd. 28 General Biologicals Corporation 29 GlaxoSmithKline Plc 30 Grupo Ferrer Internacional, S.A. 31 Hsiri Therapeutics, LLC 32 iCo Therapeutics Inc. 33 Nanomerics Ltd 34 Novabiotics Limited 35 NovaDigm Therapeutics, Inc. 36 Onxeo SA 37 Panacela Labs, Inc. 38 Scynexis, Inc. 39 Sealife PHARMA GMBH 40 Sequella, Inc. 41 Viamet Pharmaceuticals, Inc. 42 Wellstat Vaccines, LLC 43 Candidiasis - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Target 45 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 AC-17 - Drug Profile 53 amphotericin b - Drug Profile 54 amphotericin B - Drug Profile 55 arasertaconazole - Drug Profile 56 AUGC-10 - Drug Profile 57 AUGC-15 - Drug Profile 58 candida vaccine - Drug Profile 59 candida vaccine - Drug Profile 60 candidiasis oligosaccharide vaccine - Drug Profile 61 CD-101 - Drug Profile 62 CTIX-1502 - Drug Profile 64 DWP-06081 - Drug Profile 65 E-1210 - Drug Profile 66 E-1211 - Drug Profile 67 Forazoline A - Drug Profile 68 KSL-W - Drug Profile 69 MH-010 - Drug Profile 70 miconazole - Drug Profile 71 Monoclonal Antibodies to Target Fba for Candidiasis - Drug Profile 72 mutanobactins - Drug Profile 73 Myc-102 - Drug Profile 74 NDV-3 - Drug Profile 75 NDV-3A - Drug Profile 77 NP-339 - Drug Profile 78 obliquumol - Drug Profile 79 PAC-113 - Drug Profile 80 pegylated amphotericin B - Drug Profile 82 PMX-1408 - Drug Profile 83 PMX-1570 - Drug Profile 85 PMX-1576 - Drug Profile 86 PMX-1591 - Drug Profile 87 PMX-1625 - Drug Profile 88 PMX-519 - Drug Profile 89 PMX-70004 - Drug Profile 90 Prof-002 - Drug Profile 91 Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 92 SCY-078 - Drug Profile 93 SLP-0901 - Drug Profile 95 SLP-0904 - Drug Profile 96 Small Molecule for Candidiasis - Drug Profile 97 Small Molecule for Fungal Infections - Drug Profile 98 Small Molecule for Systemic Candidiasis - Drug Profile 99 Small Molecules for Aspergillosis and Candidiasis - Drug Profile 100 Small Molecules for Candidiasis - Drug Profile 101 Small Molecules for Candidiasis - Drug Profile 102 Small Molecules for Candidiasis - Drug Profile 103 Small Molecules for Fungal Infections - Drug Profile 104 SQ-109 - Drug Profile 105 VT-1161 - Drug Profile 109 XELRYX-3 - Drug Profile 111 Candidiasis - Recent Pipeline Updates 112 Candidiasis - Dormant Projects 123 Candidiasis - Discontinued Products 125 Candidiasis - Product Development Milestones 126 Featured News & Press Releases 126 Appendix 135 Methodology 135 Coverage 135 Secondary Research 135 Primary Research 135 Expert Panel Validation 135 Contact Us 135 Disclaimer 136
List of Tables
Number of Products under Development for Candidiasis, H2 2015 13 Number of Products under Development for Candidiasis - Comparative Analysis, H2 2015 14 Number of Products under Development by Companies, H2 2015 16 Number of Products under Investigation by Universities/Institutes, H2 2015 17 Comparative Analysis by Late Stage Development, H2 2015 18 Comparative Analysis by Clinical Stage Development, H2 2015 19 Comparative Analysis by Early Stage Development, H2 2015 20 Comparative Analysis by Unknown Stage Development, H2 2015 21 Products under Development by Companies, H2 2015 22 Products under Development by Companies, H2 2015 (Contd..1) 23 Products under Development by Companies, H2 2015 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2015 25 Candidiasis - Pipeline by Aureogen Biosciences, Inc., H2 2015 26 Candidiasis - Pipeline by Bakker Medical Srl, H2 2015 27 Candidiasis - Pipeline by Biomar Microbial Technologies, H2 2015 28 Candidiasis - Pipeline by Cellceutix Corporation, H2 2015 29 Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2015 30 Candidiasis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 31 Candidiasis - Pipeline by Eisai Co., Ltd., H2 2015 32 Candidiasis - Pipeline by General Biologicals Corporation, H2 2015 33 Candidiasis - Pipeline by GlaxoSmithKline Plc, H2 2015 34 Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015 35 Candidiasis - Pipeline by Hsiri Therapeutics, LLC, H2 2015 36 Candidiasis - Pipeline by iCo Therapeutics Inc., H2 2015 37 Candidiasis - Pipeline by Nanomerics Ltd, H2 2015 38 Candidiasis - Pipeline by Novabiotics Limited, H2 2015 39 Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2015 40 Candidiasis - Pipeline by Onxeo SA, H2 2015 41 Candidiasis - Pipeline by Panacela Labs, Inc., H2 2015 42 Candidiasis - Pipeline by Scynexis, Inc., H2 2015 43 Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2015 44 Candidiasis - Pipeline by Sequella, Inc., H2 2015 45 Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2015 46 Candidiasis - Pipeline by Wellstat Vaccines, LLC, H2 2015 47 Assessment by Monotherapy Products, H2 2015 48 Number of Products by Stage and Target, H2 2015 50 Number of Products by Stage and Mechanism of Action, H2 2015 52 Number of Products by Stage and Route of Administration, H2 2015 54 Number of Products by Stage and Molecule Type, H2 2015 56 Candidiasis Therapeutics - Recent Pipeline Updates, H2 2015 116 Candidiasis - Dormant Projects, H2 2015 127 Candidiasis - Dormant Projects (Contd..2), H2 2015 128 Candidiasis - Discontinued Products, H2 2015 129
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
